Leucine-Rich Repeat Kinase 2 (LRRK2) Cellular Biology: A Review of Recent Advances in Identifying Physiological Substrates and Cellular Functions

REFERENCES

• Andres-Mateos, E., Mejias, R., Sasaki, M., Li, X., Lin, B. M., Biskup, S., Zhang, L., Banerjee, R., Thomas, B., Yang, L., Liu, G., Beal, M. F., Huso, D. L., Dawson T. M., & Dawson V. L. (2009). Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J Neurosci, 29, 15846–15850.
   PubMed Web of Science ®Google Scholar
• Bonifati, V. (2007). LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson’s disease. Neurochem Res 32, 1700–1708.
   Google Scholar
• Chartier-Harlin, M. C., Dachsel, J. C., Vilarino-Guell, C., Lincoln, S. J., Lepretre, F., Hulihan, M. M., Kachergus, J., Milnerwood, A. J., Tapia, L., Song, M. S., Le Rhun, E., Mutez, E., Larvor, L., Duflot, A., Vanbesien-Mailliot, C., Kreisler, A., Ross, O. A., Nishioka, K., Soto-Ortolaza, A. I., Cobb, S. A., Melrose, H. L., Behrouz, B., Keeling, B. H., Bacon, J. A., Hentati, E., Williams, L., Yanagiya, A., Sonenberg, N., Lockhart, P. J., Zubair, A. C., Uitti, R. J., Aasly, J. O., Krygowska-Wajs, A., Opala, G., Wszolek, Z. K., Frigerio, R., Maraganore, D. M., Gosal, D., Lynch, T., Hutchinson, M., Bentivoglio, A. R., Valente, E. M., Nichols, W. C., Pankratz, N., Foroud, T., Gibson, R. A., Hentati, F., Dickson, D. W., Destee, A., & Farrer, M. J. (2011). Translation initiator EIF4G1 mutations in familial parkinson disease. Am J Hum Genet 89, 398–406.
   PubMed Web of Science ®Google Scholar
• Correia Guedes, L., Ferreira, J. J., Rosa, M. M., Coelho, M., Bonifati, V., & Sampaio, C. (2010). Worldwide frequency of G2019S LRRK2 mutation in Parkinson’s disease: A systematic review. Parkinsonism Relat Disord 16, 237–242.
   Google Scholar
• Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J. D., Patricelli, M. P., Nomanbhoy, T. K., Alessi, D. R., & Gray, N. S. (2011). Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2. Nat Chem Biol 7, 203–205.
   PubMed Web of Science ®Google Scholar
• Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., & Tanner, C. M. (2007). Projected number of people with Parkinson disease in the most populous nations, 2005 through, 2030. Neurology 68, 384–386.
   PubMed Web of Science ®Google Scholar
• Dzamko, N., Deak, M., Hentati, F., Reith, A. D., Prescott, A. R., Alessi, D. R., & Nichols, R. J. (2010). Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem 430, 405–413.
   Google Scholar
• Fadden, P., Haystead, T. A., & Lawrence, J. C., Jr. (1997). Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and rapamycin in rat adipocytes. J Biol Chem 272, 10240–10247.
   PubMed Web of Science ®Google Scholar
• Fu, H., Subramanian, R. R., & Masters, S. C. (2000). 14-3-3 proteins: Structure, function, and regulation. Annu Rev Pharmacol Toxicol 40, 617–647.
   PubMed Web of Science ®Google Scholar
• Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S., & Obata, F. (2002). A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 51, 296–301.
   PubMed Web of Science ®Google Scholar
• Gingras, A. C., Raught, B., Gygi, S. P., Niedzwiecka, A., Miron, M., Burley, S. K., Polakiewicz, R. D., Wyslouch-Cieszynska, A., Aebersold, R., & Sonenberg, N. (2001). Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15, 2852–2864.
   PubMed Web of Science ®Google Scholar
• Gloeckner, C. J., Schumacher, A., Boldt, K., & Ueffing, M. (2009). The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem 109, 959–968.
   PubMed Web of Science ®Google Scholar
• Greggio, E., Taymans, J. M., Zhen, E. Y., Ryder, J., Vancraenenbroeck, R., Beilina, A., Sun, P., Deng, J., Jaffe, H., Baekelandt, V., Merchant, K., & Cookson, M. R. (2009). The Parkinson’s disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem Biophys Res Commun 389, 449–454.
   Google Scholar
• Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., Ahmad, R., Miller, D. W., Kesavapany, S., Singleton, A., Lees, A., Harvey, R. J., Harvey, K., & Cookson, M. R. (2006). Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23, 329–341.
   PubMed Web of Science ®Google Scholar
• Halpain, S., & Dehmelt, L. (2006). The MAP1 family of microtubule-associated proteins. Genome Biol 7, 224.
   Google Scholar
• Healy, D. G., Falchi, M., O’Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., Ferreira, J. J., Tolosa, E., Kay, D. M., Klein, C., Williams, D. R., Marras, C., Lang, A. E., Wszolek, Z. K., Berciano, J., Schapira, A. H., Lynch, T., Bhatia, K. P., Gasser, T., Lees, A. J., & Wood, N. W. (2008). Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: A case-control study. Lancet Neurol 7, 583–590.
   PubMed Web of Science ®Google Scholar
• Heesom, K. J., Avison, M. B., Diggle, T. A., & Denton, R. M. (1998). Insulin-stimulated kinase from rat fat cells that phosphorylates initiation factor 4E-binding protein 1 on the rapamycin-insensitive site (serine-111). Biochem J 336 (Pt l), 39–48.
   Google Scholar
• Hudkins, R. L., Diebold, J. L., Tao, M., Josef, K. A., Park, C. H., Angeles, T. S., Aimone, L. D., Husten, J., Ator, M. A., Meyer, S. L., Holskin, B. P., Durkin, J. T., Fedorov, A. A., Fedorov, E. V., Almo, S. C., Mathiasen, J. R., Bozyczko-Coyne, D., Saporito, M. S., Scott, R. W., & Mallamo, J. P. (2008). Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: Optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models. J Med Chem 51, 5680–5689.
   PubMed Web of Science ®Google Scholar
• Hummel, T., Krukkert, K., Roos, J., Davis, G., & Klambt, C. (2000). Futsch/22C10 is a MAP1B-like protein required for dendritic and axonal development. Neuron 26, 357–370.
   PubMed Web of Science ®Google Scholar
• Imai, Y., Gehrke, S., Wang, H. Q., Takahashi, R., Hasegawa, K., Oota, E., & Lu, B. (2008). Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in . Drosophila. EMBO J 27, 2432–2443.
   PubMed Web of Science ®Google Scholar
• Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., & Kuriyan, J. (2011). Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell 42, 9–22.
   PubMed Web of Science ®Google Scholar
• Kamikawaji, S., Ito, G., & Iwatsubo, T. (2009). Identification of the autophosphorylation sites of LRRK2. Biochemistry 48, 10963–10975.
   PubMed Web of Science ®Google Scholar
• Kumar, A., Greggio, E., Beilina, A., Kaganovich, A., Chan, D., Taymans, J. M., Wolozin, B., & Cookson, M. R. (2010). The Parkinson’s disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One 5, e8730.
   Google Scholar
• Lee, S., Liu, H. P., Lin, W. Y., Guo, H., & Lu, B. (2010). LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the neuromuscular junction. J Neurosci 30, 16959–16969.
   PubMed Web of Science ®Google Scholar
• Li, X., Wang, Q. J., Pan, N., Lee, S., Zhao, Y., Chait, B. T., & Yue, Z. (2011). Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson’s disease. PLoS One 6, e17153.
   PubMed Web of Science ®Google Scholar
• Liao, X. H., Majithia, A., Huang, X., & Kimmel, A. R. (2008). Growth control via TOR kinase signaling, an intracellular sensor of amino acid and energy availability, with crosstalk potential to proline metabolism. Amino Acids 35, 761–770.
   PubMedGoogle Scholar
• Marras, C., Schuele, B., Munhoz, R. P., Rogaeva, E., Langston, J. W., Kasten, M., Meaney, C., Klein, C., Wadia, P. M., Lim, S. Y., Chuang, R. S., Zadikof, C., Steeves, T., Prakash, K. M., de Bie, R. M., Adeli, G., Thomsen, T., Johansen, K. K., Teive, H. A., Asante, A., Reginold, W., & Lang, A. E. (2011). Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 77, 325–333.
   PubMed Web of Science ®Google Scholar
• Matus, A. (1991). Microtubule-associated proteins and neuronal morphogenesis. J Cell Sci Suppl 15, 61–67.
   PubMedGoogle Scholar
• Melrose, H. L., Dachsel, J. C., Behrouz, B., Lincoln, S. J., Yue, M., Hinkle, K. M., Kent, C. B., Korvatska, E., Taylor, J. P., Witten, L., Liang, Y. Q., Beevers, J. E., Boules, M., Dugger, B. N., Serna, V. A., Gaukhman, A., Yu, X., Castanedes-Casey, M., Braithwaite, A. T., Ogholikhan, S., Yu, N., Bass, D., Tyndall, G., Schellenberg, G. D., Dickson, D. W., Janus, C., & Farrer, M. J. (2010). Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 40, 503–517.
   PubMed Web of Science ®Google Scholar
• Morrison, D. K. (2009). The 14-3-3 proteins: Integrators of diverse signaling cues that impact cell fate and cancer development., Trends Cell Biol 19, 16–23.
   PubMed Web of Science ®Google Scholar
• Nalls, M. A., Plagnol, V., Hernandez, D. G., Sharma, M., Sheerin, U. M., Saad, M., Simon-Sanchez, J., Schulte, C., Lesage, S., Sveinbjornsdottir, S., Stefansson, K., Martinez, M., Hardy, J., Heutink, P., Brice, A., Gasser, T., Singleton, A. B., & Wood, N. W. (2011). Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: A meta-analysis of genome-wide association studies. Lancet 377, 641–649.
   PubMed Web of Science ®Google Scholar
• Nichols, R. J., Dzamko, N., Morrice, N. A., Campbell, D. G., Deak, M., Ordureau, A., Macartney, T., Tong, Y., Shen, J., Prescott, A. R., & Alessi, D. R. (2010). 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson’s disease-associated mutations and regulates cytoplasmic localization. Biochem J 430, 393–404.
   PubMed Web of Science ®Google Scholar
• Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A. M., Khan, N., Johnson, J., Martinez, J. R., Nicholl, D., Carrera, I. M., Pena, A. S., de Silva, R., Lees, A., Marti-Masso, J. F., Perez-Tur, J., Wood, N. W., & Singleton, A. B. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44, 595–600.
   PubMed Web of Science ®Google Scholar
• Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., & Regan, J. (2002). Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9, 268–272.
   PubMedGoogle Scholar
• Parisiadou, L., Xie, C., Cho, H. J., Lin, X., Gu, X. L., Long, C. X., Lobbestael, E., Baekelandt, V., Taymans, J. M., Sun, L., & Cai, H. (2009). Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 29, 13971–13980.
   PubMed Web of Science ®Google Scholar
• Pyronnet, S., Imataka, H., Gingras, A. C., Fukunaga, R., Hunter, T., & Sonenberg, N. (1999). Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J 18, 270–279.
   PubMed Web of Science ®Google Scholar
• Ramonet, D., Daher, J. P., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., Liu, Y., Swing, D. A., Beal, M. F., Troncoso, J. C., McCaffery, J. M., Jenkins, N. A., Copeland, N. G., Galter, D., Thomas, B., Lee, M. K., Dawson, T. M., Dawson, V. L., & Moore, D. J. (2011). Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 6, e18568.
   PubMed Web of Science ®Google Scholar
• Rhoads, R. E. (2009). eIF4E: New family members, new binding partners, new roles. Biol Chem 284, 16711–16715.
   Google Scholar
• Roos, J., Hummel, T., Ng, N., Klambt, C., & Davis, G. W. (2000). Futsch regulates synaptic microtubule organization and is necessary for synaptic growth. Neuron 26, 371–382.
   PubMed Web of Science ®Google Scholar
• Ross, O. A., Soto-Ortolaza, A. I., Heckman, M. G., Aasly, J. O., Abahuni, N., Annesi, G., Bacon, J. A., Bardien, S., Bozi, M., Brice, A., Brighina, L., Van Broeckhoven, C., Carr, J., Chartier-Harlin, M. C., Dardiotis, E., Dickson, D. W., Diehl, N. N., Elbaz, A., Ferrarese, C., Ferraris, A., Fiske, B., Gibson, J. M., Gibson, R., Hadjigeorgiou, G. M., Hattori, N., Ioannidis, J. P., Jasinska-Myga, B., Jeon, B. S., Kim, Y. J., Klein, C., Kruger, R., Kyratzi, E., Lesage, S., Lin, C. H., Lynch, T., Maraganore, D. M., Mellick, G. D., Mutez, E., Nilsson, C., Opala, G., Park, S. S., Puschmann, A., Quattrone, A., Sharma, M., Silburn, P. A., Sohn, Y. H., Stefanis, L., Tadic, V., Theuns, J., Tomiyama, H., Uitti, R. J., Valente, E. M., van de Loo, S., Vassilatis, D. K., Vilarino-Guell, C., White, L. R., Wirdefeldt, K., Wszolek, Z. K., Wu, R. M., & Farrer, M. J. (2011). Association of LRRK2 exonic variants with susceptibility to Parkinson’s disease: A case-control study. Lancet Neurol.
   Google Scholar
• Rudenko, I. N., & Cookson, M. R. (2010). 14-3-3 proteins are promising LRRK2 interactors. Biochem J 430, e5–e6.
   Google Scholar
• Saha, S., Guillily, M. D., Ferree, A., Lanceta, J., Chan, D., Ghosh, J., Hsu, C. H., Segal, L., Raghavan, K., Matsumoto, K., Hisamoto, N., Kuwahara, T., Iwatsubo, T., Moore, L., Goldstein, L., Cookson, M., & Wolozin, B. (2009). LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 29, 9210–9218.
   PubMed Web of Science ®Google Scholar
• Saunders-Pullman, R., Stanley, K., Wang, C., San Luciano, M., Shanker, V., Hunt, A., Severt, L., Raymond, D., Ozelius, L. J., Lipton, R. B., & Bressman, S. B. (2011). Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurology 77, 319–324.
   PubMed Web of Science ®Google Scholar
• Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000). Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289, 1938–1942.
   PubMed Web of Science ®Google Scholar
• Schoenfeld, T. A., & Obar, R. A. (1994). Diverse distribution and function of fibrous microtubule-associated proteins in the nervous system. Int Rev Cytol 151, 67–137.
   PubMed Web of Science ®Google Scholar
• Shan, Y., Seeliger, M. A., Eastwood, M. P., Frank, F., Xu, H., Jensen, M. O., Dror, R. O., Kuriyan, J., & Shaw, D. E. (2009). A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci U S A 106, 139–144.
   PubMed Web of Science ®Google Scholar
• Shulman, J. M., De Jager, P. L., & Feany, M. B. (2011). Parkinson’s disease: Genetics and pathogenesis. Annu Rev Pathol 6, 193–222.
   PubMed Web of Science ®Google Scholar
• Tain, L. S., Mortiboys, H., Tao, R. N., Ziviani, E., Bandmann, O., & Whitworth, A. J. (2009). Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci 12, 1129–1135.
   PubMed Web of Science ®Google Scholar
• Teleman, A. A., Chen, Y. W., & Cohen, S. M. (2005). 4E-BP functions as a metabolic brake used under stress conditions but not during normal growth. Genes Dev 19, 1844–1848.
   PubMed Web of Science ®Google Scholar
• Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R. J., 3rd, & Shen, J. (2010). Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci USA 107, 9879–9884.
   PubMed Web of Science ®Google Scholar
• Van Den Eeden, S. K., Tanner, C. M., Bernstein, A. L., Fross, R. D., Leimpeter, A., Bloch, D. A., & Nelson, L. M. (2003). Incidence of Parkinson’s disease: Variation by age, gender, and race/ethnicity. Am J Epidemiol 157, 1015–1022.
   PubMed Web of Science ®Google Scholar
• Vandecandelaere, A., Pedrotti, B., Utton, M. A., Calvert, R. A., & Bayley, P. M. (1996). Differences in the regulation of microtubule dynamics by microtubule-associated proteins MAP1B and MAP2. Cell Motil Cytoskeleton 35, 134–146.
   PubMed Web of Science ®Google Scholar
• Wang, D., Tang, B., Zhao, G., Pan, Q., Xia, K., Bodmer, R., & Zhang, Z. (2008). Dispensable role of ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol Neurodegener 3, 3.
   PubMed Web of Science ®Google Scholar
• Webber, P. J., Smith, A. D., Sen, S., Renfrow, M. B., Mobley, J. A., & West, A. B. (2011). Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J Mol Biol 412, 94–110.
   Google Scholar
• Westerlund, M., Belin, A. C., Anvret, A., Bickford, P., Olson, L., & Galter, D. (2008). Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson’s disease. Neuroscience 152, 429–436.
   PubMed Web of Science ®Google Scholar
• Zhou, H., Huang, C., Tong, J., Hong, W. C., Liu, Y. J., & Xia, X. G. (2011). Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int J Biol Sci 7, 753–761.
   Google Scholar
• Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., Stoessl, A. J., Pfeiffer, R. F., Patenge, N., Carbajal, I. C., Vieregge, P., Asmus, F., Muller-Myhsok, B., Dickson, D. W., Meitinger, T., Strom, T. M., Wszolek, Z. K., & Gasser, T. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601–607.
   PubMed Web of Science ®Google Scholar